close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

Kodu・Aktsiate loetelu・Nektar Therapeutics
Search

Nektar Therapeutics

Avatud

84.1 2.75

Tugev "osta" hinnang

Hinna uuendus 30. apr 2026, 14:43 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

81.57

Max

84.9

Põhinäitajad

By Trading Economics

Sissetulek

-557K

-36M

Müük

10M

22M

Aktsiakasum

-1.29

Kasumimarginaal

-165.447

Töötajad

63

EBITDA

10M

-19M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+65.11% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

946M

2.9B

Eelmine avamishind

81.35

Eelmine sulgemishind

84.1

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

0.5949 / 0.7406 Toetus ja vastupanu

Nektar Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 23:53 UTC

Tulu

Naver Posts Weaker First-Quarter Earnings

DJ

Loe

29. apr 2026, 23:41 UTC

Kuumad aktsiad

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

DJ

Loe

29. apr 2026, 23:55 UTC

Tulu

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

DJ

Loe

29. apr 2026, 23:54 UTC

Tulu

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

DJ

Loe

29. apr 2026, 23:52 UTC

Tulu

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

DJ

Loe

29. apr 2026, 23:51 UTC

Tulu

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

DJ

Loe

29. apr 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

DJ

Loe

29. apr 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

DJ

Loe

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

DJ

Loe

29. apr 2026, 23:24 UTC

Tulu

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

DJ

Loe

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

DJ

Loe

29. apr 2026, 23:24 UTC

Tulu

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

DJ

Loe

29. apr 2026, 23:22 UTC

Tulu

China Longyuan 1Q Net CNY1.70B, Down 14%

DJ

Loe

29. apr 2026, 23:22 UTC

Tulu

China Longyuan: Power Generation Down 2.9% as of End-March

DJ

Loe

29. apr 2026, 23:20 UTC

Tulu

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

DJ

Loe

29. apr 2026, 23:20 UTC

Tulu

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

DJ

Loe

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

DJ

Loe

29. apr 2026, 23:19 UTC

Tulu

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

DJ

Loe

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

DJ

Loe

29. apr 2026, 23:19 UTC

Tulu

China Vanke 1Q Loss Narrows>000002.SZ

DJ

Loe

29. apr 2026, 23:18 UTC

Tulu

Naver1Q Net Profit Missed FactSet-Compiled Consensus

DJ

Loe

29. apr 2026, 23:17 UTC

Tulu

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

DJ

Loe

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

DJ

Loe

29. apr 2026, 23:15 UTC

Tulu

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

DJ

Loe

29. apr 2026, 23:13 UTC

Tulu

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

DJ

Loe

29. apr 2026, 23:12 UTC

Tulu

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

DJ

Loe

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

DJ

Loe

29. apr 2026, 23:11 UTC

Tulu

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

DJ

Loe

29. apr 2026, 23:04 UTC

Tulu

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

DJ

Loe

29. apr 2026, 23:04 UTC

Tulu

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Nektar Therapeutics Prognoos

Hinnasiht

By TipRanks

65.11% tõus

12 kuu keskmine prognoos

Keskmine 138.38 USD  65.11%

Kõrge 185 USD

Madal 95 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Nektar Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Põhineb 8 analüütiku instrumendi Nektar Therapeutics aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.5949 / 0.7406Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Strong Bearish Evidence

All events are bearish.

Pikk perspektiiv

Bearish Evidence

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Muud aktsiad sektorist

JNJ

Johnson and Johnson

230.49

↑ +2.4%

UNH

UnitedHealth Group Inc

366.37

↓-0.47%

TMO

Thermo Fisher Scientific Inc

470.56

↑ +0.12%

ISRG

Intuitive Surgical Inc

450.54

↓-0.34%

ABT

Abbott Laboratories

90.55

↓-2%
help-icon Live chat